カテゴリー： MarketsandMarkets, 世界, 医療/バイオ

世界の血液スクリーニング市場（～2028年）：製品別（試薬＆キット、機器、ソフトウェア）、技術別（NAT、（リアルタイムPCR）、ELISA（化学発光免疫測定）、迅速検査、ウェスタンブロット）、エンドユーザー別（血液銀行、病院）、地域別

◆英語タイトル：Blood Screening Market by Product (Reagent & Kits, Instrument, Software), Technology (NAT, (Real-Time PCR), ELISA (Chemiluminescence Immunoassay), Rapid Test, Western Blot), End User (Blood Bank, Hospital), & Region - Global Forecast to 2028
	◆商品コード：MD3687-23 ◆発行会社（リサーチ会社）：MarketsandMarkets ◆発行日：2023年10月17日 ◆ページ数：253 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後24時間以内） ◆調査対象地域：グローバル ◆産業分野：医療機器

◆販売価格オプション（消費税別）

Single User（1名様閲覧）	USD4,950 ⇒換算￥752,400	見積依頼/購入/質問フォーム
Multi User (Five User)	USD6,650 ⇒換算￥1,010,800	見積依頼/購入/質問フォーム
Corporate License (全社内共有可)	USD8,150 ⇒換算￥1,238,800	見積依頼/購入/質問フォーム

★MarketsandMarketsに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

"世界の血液スクリーニング市場は2023年の24億米ドルから2028年には34億米ドルに達すると予測され、予測期間中のCAGRは7.2%" この市場の成長の主な原動力は、献血の必要性の高まり、世界的な献血数の増加、増え続ける感染症です。しかし、血液スクリーニング機器とキットの高価格と技術者の不足は、血液スクリーニング市場の成長を妨げる可能性があります。

"予測期間中、血液スクリーニング市場において、製品・サービス別では試薬・キット分野が最も高い成長率を占め"
血液スクリーニング市場は、製品によって試薬＆キット、機器、ソフトウェア＆サービスに区分されます。2022年、血液スクリーニング市場で最も高い成長率を占めたのは試薬＆キット分野でした。市場成長の主な要因は、輸血数と献血数の増加によるものです。また、血液スクリーニング技術の技術的進歩や手術件数の増加がこのセグメントの成長を刺激しています。

"血液銀行セグメントが最も高いCAGRを占め"
エンドユーザーに基づいて、血液スクリーニング市場は血液銀行と病院にセグメント化されます。2022年には、血液銀行セグメントが最も高い成長率を占めました。これは、臓器移植手術数の増加、血液の安全性に関する意識の高まりによるものです。

"アジア太平洋：最も急成長している地域の血液スクリーニング市場"
世界の血液スクリーニング市場は、北米、欧州、アジア太平洋地域、中南米、中東・アフリカに分けられます。予測期間中に最も高いCAGRを記録すると予測されているのはアジア太平洋地域です。一人当たり所得の増加、APAC諸国における地方への民間病院の進出、APAC諸国における高齢者人口の増加（慢性疾患の有病率の上昇と相まって）、同地域における高成長市場の存在などが、医療支出の増加に寄与しています。この地域の良好な規制環境と低い人件費も、市場の成長を促進すると予想されています。
.
供給側の一次面接の内訳
- 企業タイプ別ティア1（40％）、ティア2（30％）、ティア3（30%）
- 役職別 Cレベル（27％）、ディレクターレベル（18％）、その他（55%）
- 地域別北米(51%)、欧州(21%)、アジア太平洋(18%)、中南米(6%)、中東・アフリカ(4%)

主な企業は、F. Hoffmann-La Roche Ltd. (Switzerland), Grifols (Spain), Abbott Laboratories, Inc. (US), Bio-Rad Laboratories, Inc. (US), Danaher (Beckman Coulter, Inc.) (US), bioMérieux (France), Hologic (US), Thermo Fisher Scientific, Inc. (US), Becton, Dickinson and Company (US), DiaSorin (Italy), Siemens Healthineers (Germany), QuidelOrtho Corporation (US), Merck KGaA (Germany), Revvity (Earlier known as PerkinElmer Inc.) (US), Bio-Techne Corporation (US), GFE (Germany), Trinity Biotech (Ireland), Mindray (China), Maccura Biotechnology Co., Ltd. (China), Immucor, Inc. (US), Cellabs (Australia), Abnova Corporation (Taiwan), Enzo Biochem, Inc. (US), J. Mitra & Co. Pvt. Ltd. (India) and Tulip Diagnostics (India).などです。

調査範囲
この調査レポートは、血液スクリーニング市場を製品＆サービス、技術、エンドユーザー、地域別に分類しています。血液スクリーニング市場の成長に影響を与える促進要因、阻害要因、課題、機会などの主要要因に関する詳細情報を網羅しています。主要な業界プレイヤーの詳細な分析により、事業概要、ソリューション、サービス、主要戦略、契約、パートナーシップ、協定、新製品・サービスの発表、M&A、血液スクリーニング市場に関連する最近の動向に関する洞察を提供します。血液スクリーニング市場のエコシステムにおける今後の新興企業の競争分析もカバーしています。

本レポートを購入する理由
本レポートは、血液スクリーニング市場全体とサブセグメントの収益数の最も近い近似値に関する情報で、この市場の市場リーダー/新規参入者を支援します。本レポートは、利害関係者が競争状況を理解し、自社の事業をより良く位置づけ、適切な市場参入戦略を計画するためのより多くの洞察を得るのに役立ちます。また、当レポートは、関係者が市場の鼓動を理解するのに役立ち、主要な市場促進要因、阻害要因、課題、機会に関する情報を提供します。

本レポートは、以下のポイントに関する洞察を提供します：
- 血液スクリーニング市場の成長に影響を与える主な促進要因（献血数の増加、感染症の増加、技術進歩の拡大）、阻害要因（代替技術）、機会（APACの新興経済圏からの需要増加、企業間連携の増加、業界団体、政府の認識）、課題（血液スクリーニング製品の高コスト）の分析を行っています。
- 製品開発/イノベーション：血液スクリーニング市場における今後の技術、研究開発活動、新製品・サービス開始に関する詳細な洞察を提供します。
- 市場開発：有利な市場に関する包括的情報 - 当レポートでは、様々な地域の血液スクリーニング市場を分析しています。
- 市場の多様化：血液スクリーニング市場における新製品＆サービス、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。
- 競合評価：F. Hoffmann-La Roche Ltd. (Switzerland), Grifols (Spain), Abbott Laboratories, Inc. (US), Bio-Rad Laboratories, Inc. (US), Danaher (Beckman Coulter, Inc.) (US), bioMérieux (France)などの企業情報が含まれています。

1 イントロダクション
2 調査方法
3 エグゼクティブサマリー
4 プレミアムインサイト
5 市場概要
6 血液スクリーニングの世界市場：製品・サービス別
7 血液スクリーニングの世界市場：技術別
8 血液スクリーニングの世界市場：エンドユーザー別
9 血液スクリーニングの世界市場：地域別
10 競争状況
11 企業情報
12 付録

❖ レポートの目次 ❖

1 INTRODUCTION 33
1.1 STUDY OBJECTIVES 33
1.2 MARKET DEFINITION 33
1.2.1 INCLUSIONS AND EXCLUSIONS 34
1.3 MARKET SCOPE 35
1.3.1 BLOOD SCREENING MARKET 35
1.3.2 REGIONS COVERED 36
1.4 YEARS CONSIDERED 36
1.5 CURRENCY CONSIDERED 37
1.6 LIMITATIONS 37
1.7 STAKEHOLDERS 37
1.8 SUMMARY OF CHANGES 37
1.9 RECESSION IMPACT 38
2 RESEARCH METHODOLOGY 39
2.1 RESEARCH DATA 39
2.2 RESEARCH APPROACH 39
FIGURE 1 BLOOD SCREENING MARKET: RESEARCH DESIGN METHODOLOGY 39
2.2.1 SECONDARY DATA 40
2.2.1.1 Key data from secondary sources 40
2.2.2 PRIMARY DATA 41
2.2.2.1 Primary sources 42
2.2.2.2 Key data from primary sources 42
2.2.2.3 Key industry insights 43
2.2.2.4 Breakdown of primary interviews 44
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 44
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 44
2.3 MARKET SIZE ESTIMATION 45
2.3.1 BOTTOM-UP APPROACH 45
2.3.1.1 Approach 1: Company revenue estimation approach 45
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 45
2.3.1.2 Approach 2: Presentations of companies and primary interviews 46
2.3.1.3 Growth forecast 46
2.3.1.4 CAGR projections 46
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 46
2.3.2 TOP-DOWN APPROACH 47
FIGURE 6 BLOOD SCREENING MARKET: TOP-DOWN APPROACH 47
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 48
FIGURE 7 DATA TRIANGULATION METHODOLOGY 48
2.5 MARKET SHARE ANALYSIS 49
2.6 STUDY ASSUMPTIONS 49
2.7 GROWTH RATE ASSUMPTIONS 50
2.8 RISK ASSESSMENT 50
2.8.1 RISK ASSESSMENT ANALYSIS 50
2.9 RECESSION IMPACT ANALYSIS 50
3 EXECUTIVE SUMMARY 52
FIGURE 8 BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 52
FIGURE 9 BLOOD SCREENING MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 53
FIGURE 10 BLOOD SCREENING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 53
FIGURE 11 BLOOD SCREENING MARKET, BY REGION, 2023 VS. 2028 (USD MILLION) 54
4 PREMIUM INSIGHTS 55
4.1 BLOOD SCREENING MARKET OVERVIEW 55
FIGURE 12 INCREASING NUMBER OF BLOOD DONATIONS TO DRIVE MARKET GROWTH DURING FORECAST PERIOD 55
4.2 BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 56
FIGURE 13 REAGENTS & KITS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 56
4.3 BLOOD SCREENING MARKET, BY TECHNOLOGY, 2023 VS. 2028 56
FIGURE 14 NUCLEIC ACID TESTS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 56
4.4 BLOOD SCREENING MARKET, BY END USER, 2023 VS. 2028 57
FIGURE 15 BLOOD BANKS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 57
4.5 BLOOD SCREENING MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 57
FIGURE 16 ASIA PACIFIC REGION TO REGISTER HIGHEST GROWTH RATE FROM 2023 TO 2028 57
5 MARKET OVERVIEW 58
5.1 INTRODUCTION 58
5.2 MARKET DYNAMICS 58
FIGURE 17 BLOOD SCREENING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 58
5.2.1 DRIVERS 59
5.2.1.1 Increasing blood donations 59
5.2.1.2 Rising prevalence of infectious diseases 60
5.2.2 RESTRAINTS 60
5.2.2.1 High cost of blood screening technologies 60
5.2.3 OPPORTUNITIES 61
5.2.3.1 Rising technological advancements 61
5.2.3.2 High growth potential of emerging economies 61
5.2.4 CHALLENGES 62
5.2.4.1 Usage of low-sensitivity screening tests 62
5.2.4.2 Shortage of skilled laboratory technicians 62
5.3 PRICING ANALYSIS 63
5.3.1 PRICING MODEL ANALYSIS 63
TABLE 1 INDICATIVE PRICING ANALYSIS FOR BLOOD SCREENING PRODUCTS 63
5.3.2 AVERAGE SELLING PRICE TREND 63
TABLE 2 AVERAGE SELLING PRICE ANALYSIS OF BLOOD SCREENING PRODUCTS 63
5.3.3 AVERAGE SELLING PRICE OF BLOOD SCREENING PRODUCTS, BY KEY PLAYER 64
TABLE 3 AVERAGE SELLING PRICE OF BLOOD SCREENING PRODUCTS 64
5.4 PATENT ANALYSIS 65
5.4.1 PATENT ANALYSIS OF NUCLEIC ACID AMPLIFICATION TECHNOLOGIES 65
5.4.2 BLOOD SCREENING MARKET: LIST OF MAJOR PATENTS 66
5.5 VALUE CHAIN ANALYSIS 66
FIGURE 18 MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASE 67
5.6 SUPPLY CHAIN ANALYSIS 67
FIGURE 19 BLOOD SCREENING MARKET: SUPPLY CHAIN ANALYSIS 68
5.7 ECOSYSTEM ANALYSIS 68
FIGURE 20 BLOOD SCREENING MARKET: ECOSYSTEM MAP 69
5.7.1 BLOOD SCREENING MARKET: ECOSYSTEM ROLE 69
5.8 PORTER’S FIVE FORCES ANALYSIS 70
TABLE 4 BLOOD SCREENING MARKET: PORTER’S FIVE FORCES ANALYSIS 70
5.8.1 THREAT OF NEW ENTRANTS 70
5.8.2 THREAT OF SUBSTITUTES 70
5.8.3 BARGAINING POWER OF BUYERS 70
5.8.4 BARGAINING POWER OF SUPPLIERS 70
5.8.5 INTENSITY OF COMPETITIVE RIVALRY 71
5.9 REGULATORY LANDSCAPE 71
TABLE 5 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 71
TABLE 6 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 71
TABLE 7 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72
TABLE 8 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72
5.9.1 NORTH AMERICA 72
5.9.1.1 US 72
5.9.1.2 Canada 72
5.9.2 EUROPE 73
TABLE 9 EUROPE: CLASSIFICATION OF DEVICES 73
5.9.3 ASIA PACIFIC 74
5.9.3.1 China 74
5.9.3.2 Japan 74
TABLE 10 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 74
5.9.3.3 India 74
5.9.4 LATIN AMERICA 74
5.9.4.1 Brazil 75
5.9.5 MIDDLE EAST 75
5.10 TRADE ANALYSIS 75
5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS 75
TABLE 11 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION) 75
TABLE 12 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION) 76
5.11 TECHNOLOGY ANALYSIS 76
5.12 KEY CONFERENCES AND EVENTS 77
TABLE 13 BLOOD SCREENING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2023 −2024) 77
5.13 PESTLE ANALYSIS 78
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 79
5.14.1 REVENUE SHIFT IN BLOOD SCREENING MARKET 79
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 79
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 79
FIGURE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR BLOOD SCREENING PRODUCTS 79
TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR BLOOD SCREENING PRODUCTS (%) 80
5.15.2 BUYING CRITERIA 80
FIGURE 22 KEY BUYING CRITERIA FOR BLOOD SCREENING PRODUCTS 80
TABLE 15 KEY BUYING CRITERIA, BY PRODUCT & SERVICE 80
5.16 CASE STUDY ANALYSIS 81
5.16.1 CASE STUDY 1: OPTIMIZATION OF HBSAG QUANTITATIVE ELISA 81
5.16.2 CASE STUDY 2: CLINICAL EFFICACY OF NAT WITH ELISA 81
6 BLOOD SCREENING MARKET, BY PRODUCT & SERVICE 82
6.1 INTRODUCTION 83
TABLE 16 BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 83
6.2 REAGENTS & KITS 83
TABLE 17 KEY PRODUCTS FOR REAGENTS & KITS 84
TABLE 18 BLOOD SCREENING MARKET FOR REAGENTS & KITS, BY REGION, 2021–2028 (USD MILLION) 84
TABLE 19 BLOOD SCREENING MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 85
6.2.1 NAT REAGENTS & KITS 85
6.2.1.1 High sensitivity to drive market 85
TABLE 20 KEY PRODUCTS FOR NAT REAGENTS & KITS 86
TABLE 21 BLOOD SCREENING MARKET FOR NAT REAGENTS & KITS, BY REGION, 2021–2028 (USD MILLION) 87
TABLE 22 BLOOD SCREENING MARKET FOR NAT REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 87
6.2.2 ELISA REAGENTS & KITS 87
6.2.2.1 Ease of use and cost-effectiveness to drive market 87
TABLE 23 KEY PRODUCTS FOR ELISA REAGENTS & KITS 89
TABLE 24 BLOOD SCREENING MARKET FOR ELISA REAGENTS & KITS, BY REGION, 2021–2028 (USD MILLION) 89
TABLE 25 BLOOD SCREENING MARKET FOR ELISA REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION) 90
6.2.3 OTHER REAGENTS & KITS 90
TABLE 26 KEY PRODUCTS FOR OTHER REAGENTS & KITS 90
TABLE 27 BLOOD SCREENING MARKET FOR OTHER REAGENTS & KITS, BY REGION, 2021–2028 (USD MILLION) 91
6.3 INSTRUMENTS 91
TABLE 28 KEY PRODUCTS FOR INSTRUMENTS 92
TABLE 29 BLOOD SCREENING MARKET FOR INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION) 92
TABLE 30 BLOOD SCREENING MARKET FOR INSTRUMENTS, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 93
6.3.1 RENTAL PURCHASE 93
6.3.1.1 Reduced liability with limited financial losses to propel market 93
TABLE 31 BLOOD SCREENING MARKET FOR RENTAL PURCHASE INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION) 93
6.3.2 OUTRIGHT PURCHASE 94
6.3.2.1 Availability of government support to drive market 94
TABLE 32 BLOOD SCREENING MARKET FOR OUTRIGHT PURCHASE INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION) 94
6.4 SOFTWARE & SERVICES 94
6.4.1 RISING DEMAND ACROSS EMERGING ECONOMIES TO SUPPORT MARKET GROWTH 94
TABLE 33 KEY PRODUCTS FOR SOFTWARE & SERVICES 95
TABLE 34 BLOOD SCREENING MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021–2028 (USD MILLION) 95
7 BLOOD SCREENING MARKET, BY TECHNOLOGY 96
7.1 INTRODUCTION 97
TABLE 35 BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 97
7.2 NUCLEIC ACID TESTS (NAT) 97
TABLE 36 KEY PRODUCTS IN NAT MARKET 98
TABLE 37 BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY REGION, 2021–2028 (USD MILLION) 99
TABLE 38 BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 99
7.2.1 TRANSCRIPTION-MEDIATED AMPLIFICATION (TMA) 99
7.2.1.1 High sensitivity to support market growth 99
TABLE 39 BLOOD SCREENING MARKET FOR TMA, BY REGION, 2021–2028 (USD MILLION) 100
7.2.2 REAL-TIME POLYMERASE CHAIN REACTION (RT-PCR) 100
7.2.2.1 Elimination of contamination risks to propel market 100
TABLE 40 BLOOD SCREENING MARKET FOR RT-PCR, BY REGION, 2021–2028 (USD MILLION) 101
7.3 SEROLOGY/IMMUNOASSAYS 101
TABLE 41 KEY PRODUCTS FOR SEROLOGY/IMMUNOASSAYS 101
TABLE 42 BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY REGION, 2021–2028 (USD MILLION) 102
TABLE 43 BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 102
7.3.1 CHEMILUMINESCENT IMMUNOASSAYS (CLIA) 103
7.3.1.1 Ultra-sensitive and automated features to drive market 103
TABLE 44 BLOOD SCREENING MARKET FOR CHEMILUMINESCENT IMMUNOASSAYS, BY REGION, 2021–2028 (USD MILLION) 103
7.3.2 FLUORESCENT IMMUNOASSAYS (FIA) 103
7.3.2.1 Rising demand for safe & stable reagents to propel market 103
TABLE 45 BLOOD SCREENING MARKET FOR FLUORESCENT IMMUNOASSAYS, BY REGION, 2021–2028 (USD MILLION) 104
7.3.3 COLORIMETRIC IMMUNOASSAYS/ELISA (CI/ELISA) 104
7.3.3.1 Qualitative and quantitative antigen measurement for blood serum to drive market 104
TABLE 46 BLOOD SCREENING MARKT FOR COLORIMETRIC IMMUNOASSAYS/ELISA, BY REGION, 2021–2028 (USD MILLION) 105
7.4 RAPID TESTS 105
7.4.1 HIGH EFFICIENCY IN POC DIAGNOSTICS TO PROPEL MARKET 105
TABLE 47 KEY PRODUCTS FOR RAPID TESTS 106
TABLE 48 BLOOD SCREENING MARKET FOR RAPID TESTS, BY REGION, 2021–2028 (USD MILLION) 106
7.5 WESTERN BLOT ASSAYS 106
7.5.1 ABILITY TO DETECT RETROVIRUS ANTIBODIES TO DRIVE MARKET 106
TABLE 49 KEY PRODUCTS FOR WESTERN BLOT ASSAYS 107
TABLE 50 BLOOD SCREENING MARKET FOR WESTERN BLOT ASSAYS, BY REGION, 2021–2028 (USD MILLION) 107
7.6 NEXT-GENERATION SEQUENCING (NGS) 108
7.6.1 EMERGING TECHNOLOGY FOR HIV TESTING TO SUPPORT MARKET GROWTH 108
TABLE 51 BLOOD SCREENING MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2021–2028 (USD MILLION) 108
8 BLOOD SCREENING MARKET, BY END USER 109
8.1 INTRODUCTION 110
TABLE 52 BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 110
8.2 BLOOD BANKS 110
8.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET 110
TABLE 53 BLOOD SCREENING MARKET FOR BLOOD BANKS, BY REGION, 2021–2028 (USD MILLION) 111
8.3 HOSPITALS 111
8.3.1 INCREASING SURGICAL PROCEDURES TO PROPEL MARKET 111
TABLE 54 BLOOD SCREENING MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION) 112
9 BLOOD SCREENING MARKET, BY REGION 113
9.1 INTRODUCTION 114
TABLE 55 BLOOD SCREENING MARKET, BY REGION, 2021–2028 (USD MILLION) 114
9.2 NORTH AMERICA 114
FIGURE 23 NORTH AMERICA: BLOOD SCREENING MARKET SNAPSHOT 115
TABLE 56 NORTH AMERICA: BLOOD SCREENING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 57 NORTH AMERICA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 116
TABLE 58 NORTH AMERICA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 116
TABLE 59 NORTH AMERICA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 117
TABLE 60 NORTH AMERICA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 117
TABLE 61 NORTH AMERICA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 118
TABLE 62 NORTH AMERICA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 118
TABLE 63 NORTH AMERICA: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 119
9.2.1 NORTH AMERICA: RECESSION IMPACT 119
9.2.2 US 119
9.2.2.1 Increasing prevalence of HIV and chronic diseases to drive market 119
TABLE 64 US: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 120
TABLE 65 US: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 121
TABLE 66 US: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 121
TABLE 67 US: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 121
TABLE 68 US: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 122
TABLE 69 US: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 122
TABLE 70 US: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 122
9.2.3 CANADA 123
9.2.3.1 Rising volume of surgical procedures to drive market 123
TABLE 71 CANADA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 123
TABLE 72 CANADA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 124
TABLE 73 CANADA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 124
TABLE 74 CANADA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 124
TABLE 75 CANADA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 125
TABLE 76 CANADA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 125
TABLE 77 CANADA: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 125
9.3 EUROPE 126
TABLE 78 EUROPE: BLOOD SCREENING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 79 EUROPE: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 127
TABLE 80 EUROPE: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 127
TABLE 81 EUROPE: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 127
TABLE 82 EUROPE: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 128
TABLE 83 EUROPE: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 128
TABLE 84 EUROPE: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 129
TABLE 85 EUROPE: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 129
9.3.1 EUROPE: RECESSION IMPACT 129
9.3.2 GERMANY 130
9.3.2.1 High incidence of cancer to drive market 130
TABLE 86 GERMANY: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 130
TABLE 87 GERMANY: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 131
TABLE 88 GERMANY: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 131
TABLE 89 GERMANY: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 131
TABLE 90 GERMANY: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 132
TABLE 91 GERMANY: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 132
TABLE 92 GERMANY: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 132
9.3.3 FRANCE 133
9.3.3.1 Growing cases of HIV to propel market 133
TABLE 93 FRANCE: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 133
TABLE 94 FRANCE: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 133
TABLE 95 FRANCE: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 134
TABLE 96 FRANCE: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 134
TABLE 97 FRANCE: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 134
TABLE 98 FRANCE: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 135
TABLE 99 FRANCE: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 135
9.3.4 UK 135
9.3.4.1 Favorable government support for infectious disease screening to drive market 135
TABLE 100 UK: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 136
TABLE 101 UK: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 136
TABLE 102 UK: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 137
TABLE 103 UK: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 137
TABLE 104 UK: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 137
TABLE 105 UK: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 138
TABLE 106 UK: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 138
9.3.5 ITALY 138
9.3.5.1 Growing number of blood donors to support market growth 138
TABLE 107 ITALY: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 139
TABLE 108 ITALY: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 139
TABLE 109 ITALY: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 139
TABLE 110 ITALY: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 140
TABLE 111 ITALY: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 112 ITALY: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 141
TABLE 113 ITALY: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 141
9.3.6 SPAIN 141
9.3.6.1 Rising adoption of NAT technology to propel market 141
TABLE 114 SPAIN: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 142
TABLE 115 SPAIN: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 142
TABLE 116 SPAIN: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 142
TABLE 117 SPAIN: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 143
TABLE 118 SPAIN: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 119 SPAIN: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 144
TABLE 120 SPAIN: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 144
9.3.7 REST OF EUROPE 144
TABLE 121 GDP EXPENDITURE ON HEALTHCARE, BY COUNTRY (%) 145
TABLE 122 REST OF EUROPE: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 145
TABLE 123 REST OF EUROPE: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 145
TABLE 124 REST OF EUROPE: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 146
TABLE 125 REST OF EUROPE: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 146
TABLE 126 REST OF EUROPE: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 146
TABLE 127 REST OF EUROPE: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 147
TABLE 128 REST OF EUROPE: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 147
9.4 ASIA PACIFIC 147
FIGURE 24 ASIA PACIFIC: BLOOD SCREENING MARKET SNAPSHOT 148
TABLE 129 ASIA PACIFIC: BLOOD SCREENING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 149
TABLE 130 ASIA PACIFIC: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 149
TABLE 131 ASIA PACIFIC: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 149
TABLE 132 ASIA PACIFIC: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 150
TABLE 133 ASIA PACIFIC: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 150
TABLE 134 ASIA PACIFIC: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 150
TABLE 135 ASIA PACIFIC: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 151
TABLE 136 ASIA PACIFIC: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 151
9.4.1 ASIA PACIFIC: RECESSION IMPACT 151
9.4.2 CHINA 152
9.4.2.1 High burden of infectious diseases to drive market 152
TABLE 137 CHINA: KEY MACROINDICATORS 152
TABLE 138 CHINA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 153
TABLE 139 CHINA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 140 CHINA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 153
TABLE 141 CHINA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 154
TABLE 142 CHINA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 154
TABLE 143 CHINA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 155
TABLE 144 CHINA: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 155
9.4.3 JAPAN 155
9.4.3.1 Growing adoption of advanced blood screening technologies to drive market 155
TABLE 145 JAPAN: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 156
TABLE 146 JAPAN: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 156
TABLE 147 JAPAN: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 157
TABLE 148 JAPAN: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 157
TABLE 149 JAPAN: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 157
TABLE 150 JAPAN: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 158
TABLE 151 JAPAN: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 158
9.4.4 INDIA 158
9.4.4.1 Increasing road accidents to support market growth 158
TABLE 152 INDIA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 159
TABLE 153 INDIA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 160
TABLE 154 INDIA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 160
TABLE 155 INDIA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 160
TABLE 156 INDIA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 157 INDIA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 161
TABLE 158 INDIA: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 161
9.4.5 AUSTRALIA 162
9.4.5.1 Increasing cases of leukemia to drive market 162
TABLE 159 AUSTRALIA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 162
TABLE 160 AUSTRALIA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 162
TABLE 161 AUSTRALIA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 163
TABLE 162 AUSTRALIA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 163
TABLE 163 AUSTRALIA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 163
TABLE 164 AUSTRALIA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 164
TABLE 165 AUSTRALIA: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 164
9.4.6 REST OF ASIA PACIFIC 164
TABLE 166 REST OF ASIA PACIFIC: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 165
TABLE 167 REST OF ASIA PACIFIC: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 165
TABLE 168 REST OF ASIA PACIFIC: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 166
TABLE 169 REST OF ASIA PACIFIC: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 166
TABLE 170 REST OF ASIA PACIFIC: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 166
TABLE 171 REST OF ASIA PACIFIC: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 167
TABLE 172 REST OF ASIA PACIFIC: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 167
9.5 LATIN AMERICA 167
TABLE 173 LATIN AMERICA: BLOOD SCREENING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 168
TABLE 174 LATIN AMERICA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 168
TABLE 175 LATIN AMERICA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 169
TABLE 176 LATIN AMERICA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 169
TABLE 177 LATIN AMERICA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 169
TABLE 178 LATIN AMERICA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 170
TABLE 179 LATIN AMERICA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 170
TABLE 180 LATIN AMERICA: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 170
9.5.1 LATIN AMERICA: RECESSION IMPACT 171
9.5.2 BRAZIL 171
9.5.2.1 Growing cancer burden to support market growth 171
TABLE 181 INCIDENCE OF CANCERS IN BRAZIL, 2020 VS. 2025 171
TABLE 182 BRAZIL: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 171
TABLE 183 BRAZIL: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 184 BRAZIL: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 172
TABLE 185 BRAZIL: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 172
TABLE 186 BRAZIL: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 173
TABLE 187 BRAZIL: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 173
TABLE 188 BRAZIL: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 174
9.5.3 MEXICO 174
9.5.3.1 Rising blood donations to support market growth 174
TABLE 189 MEXICO: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 174
TABLE 190 MEXICO: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 191 MEXICO: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 175
TABLE 192 MEXICO: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 175
TABLE 193 MEXICO: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 176
TABLE 194 MEXICO: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 176
TABLE 195 MEXICO: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 176
9.5.4 REST OF LATIN AMERICA 177
TABLE 196 REST OF LATIN AMERICA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 177
TABLE 197 REST OF LATIN AMERICA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 177
TABLE 198 REST OF LATIN AMERICA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 178
TABLE 199 REST OF LATIN AMERICA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 178
TABLE 200 REST OF LATIN AMERICA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 178
TABLE 201 REST OF LATIN AMERICA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 179
TABLE 202 REST OF LATIN AMERICA: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 179
9.6 MIDDLE EAST & AFRICA 179
9.6.1 RISING SURGICAL PROCEDURES DUE TO CHRONIC DISEASES TO FUEL MARKET 179
TABLE 203 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 180
TABLE 204 MIDDLE EAST & AFRICA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2021–2028 (USD MILLION) 181
TABLE 205 MIDDLE EAST & AFRICA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2021–2028 (USD MILLION) 181
TABLE 206 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 181
TABLE 207 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET FOR NUCLEIC ACID TESTS, BY TYPE, 2021–2028 (USD MILLION) 182
TABLE 208 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET FOR SEROLOGY/IMMUNOASSAYS, BY PLATFORM, 2021–2028 (USD MILLION) 182
TABLE 209 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 183
9.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 183
10 COMPETITIVE LANDSCAPE 184
10.1 OVERVIEW 184
10.2 STRATEGIES OF KEY PLAYERS 184
10.2.1 BLOOD SCREENING MARKET: OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS 184
TABLE 210 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES 184
10.3 REVENUE SHARE ANALYSIS 186
FIGURE 25 REVENUE SHARE ANALYSIS OF LEADING PLAYERS IN BLOOD SCREENING MARKET 186
10.4 MARKET SHARE ANALYSIS 187
10.4.1 BLOOD SCREENING MARKET 187
FIGURE 26 MARKET SHARE ANALYSIS BY KEY PLAYER (2022) 187
TABLE 211 BLOOD SCREENING MARKET: INTENSITY OF COMPETITIVE RIVALRY 187
10.5 COMPANY EVALUATION MATRIX 188
10.5.1 LIST OF EVALUATED VENDORS 188
10.5.2 STARS 189
10.5.3 EMERGING LEADERS 189
10.5.4 PERVASIVE PLAYERS 189
10.5.5 PARTICIPANTS 189
FIGURE 27 BLOOD SCREENING MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022) 190
10.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 191
10.6.1 PROGRESSIVE COMPANIES 191
10.6.2 STARTING BLOCKS 191
10.6.3 RESPONSIVE COMPANIES 191
10.6.4 DYNAMIC COMPANIES 191
FIGURE 28 BLOOD SCREENING MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 192
10.7 COMPETITIVE BENCHMARKING 193
10.7.1 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS 193
FIGURE 29 BLOOD SCREENING MARKET: PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS 193
TABLE 212 BLOOD SCREENING MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS 193
TABLE 213 BLOOD SCREENING MARKET: COMPANY PRODUCT & SERVICE FOOTPRINT ANALYSIS 194
TABLE 214 BLOOD SCREENING MARKET: COMPANY REGIONAL FOOTPRINT ANALYSIS 194
TABLE 215 BLOOD SCREENING MARKET: DETAILED LIST OF KEY STARTUPS/SMES 194
10.8 COMPETITIVE SCENARIO 195
10.8.1 PRODUCT LAUNCHES 195
TABLE 216 BLOOD SCREENING MARKET: KEY PRODUCT LAUNCHES & APPROVALS (JANUARY 2020−SEPTEMBER 2023) 195
10.8.2 DEALS 196
TABLE 217 BLOOD SCREENING MARKET: KEY DEALS (JANUARY 2020−SEPTEMBER 2023) 196

11 COMPANY PROFILES 198
11.1 KEY PLAYERS 198
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 F. HOFFMANN-LA ROCHE LTD. 198
TABLE 218 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 198
FIGURE 30 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 199
11.1.2 GRIFOLS, S.A. 204
TABLE 219 GRIFOLS, S.A.: BUSINESS OVERVIEW 204
FIGURE 31 GRIFOLS S.A.: COMPANY SNAPSHOT (2022) 205
11.1.3 ABBOTT LABORATORIES 208
TABLE 220 ABBOTT LABORATORIES: BUSINESS OVERVIEW 208
FIGURE 32 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022) 209
11.1.4 BIO-RAD LABORATORIES, INC. 212
TABLE 221 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 212
FIGURE 33 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 213
11.1.5 DIASORIN 218
TABLE 222 DIASORIN: BUSINESS OVERVIEW 218
FIGURE 34 DIASORIN: COMPANY SNAPSHOT (2022) 219
11.1.6 BIOMÉRIEUX 223
TABLE 223 BIOMÉRIEUX: BUSINESS OVERVIEW 223
FIGURE 35 BIOMÉRIEUX: COMPANY SNAPSHOT (2022) 224
11.1.7 BD 226
TABLE 224 BD: BUSINESS OVERVIEW 226
FIGURE 36 BD: COMPANY SNAPSHOT (2022) 227
11.1.8 DANAHER (BECKMAN COULTER, INC.) 229
TABLE 225 DANAHER: BUSINESS OVERVIEW 229
FIGURE 37 DANAHER: COMPANY SNAPSHOT (2022) 230
11.1.9 HOLOGIC, INC. 232
TABLE 226 HOLOGIC, INC.: BUSINESS OVERVIEW 232
FIGURE 38 HOLOGIC, INC.: COMPANY SNAPSHOT (2022) 233
11.1.10 SIEMENS HEALTHINEERS AG 236
TABLE 227 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW 236
FIGURE 39 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022) 237
11.1.11 THERMO FISHER SCIENTIFIC, INC. 239
TABLE 228 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 239
FIGURE 40 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022) 240
11.2 OTHER PLAYERS 243
11.2.1 ORTHO CLINICAL DIAGNOSTICS 243
11.2.2 MERCK KGAA 244
11.2.3 REVVITY (PART OF PERKINELMER INC.) 245
11.2.4 BIO-TECHNE 246
11.2.5 GFE 247
11.2.6 TRINITY BIOTECH 248
11.2.7 J. MITRA & CO. PVT. LTD. 249
11.2.8 MINDRAY 250
11.2.9 MACCURA BIOTECHNOLOGY CO., LTD. 251
11.2.10 IMMUCOR, INC. 252
11.2.11 CELLABS 252
11.2.12 ABNOVA CORPORATION 253
11.2.13 ENZO BIOCHEM, INC. 254
11.2.14 TULIP DIAGNOSTICS PVT. LTD. 254
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

12 APPENDIX 255
12.1 DISCUSSION GUIDE 255
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 259
12.3 CUSTOMIZATION OPTIONS 261
12.4 RELATED REPORTS 261
12.5 AUTHOR DETAILS 262

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の血液スクリーニング市場（～2028年）：製品別（試薬＆キット、機器、ソフトウェア）、技術別（NAT、（リアルタイムPCR）、ELISA（化学発光免疫測定）、迅速検査、ウェスタンブロット）、エンドユーザー別（血液銀行、病院）、地域別(Blood Screening Market by Product (Reagent & Kits, Instrument, Software), Technology (NAT, (Real-Time PCR), ELISA (Chemiluminescence Immunoassay), Rapid Test, Western Blot), End User (Blood Bank, Hospital), & Region - Global Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp